CG Oncology, Inc. - Common stock (CGON)

HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.

Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations.

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.

CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects.

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024.

CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024.

A bulging pipeline of IPOs are registered, ready to go, and closely watching Reddit's performance. Here are the concerns.

The market's excited for these stocks, but there's no rush to buy them.

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on Friday a dollar below that IPO price.

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday.